Inhaled Nitric Oxide in Acute Ischemic Stroke Patients Undergoing Mechanical Thrombectomy: A Phase I Drug Pilot Research Plan

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY

The purpose of this study is to determine the safety and feasibility of using inhaled nitric oxide (iNO) in patients undergoing intra-arterial mechanical thrombectomy (blood clot extraction or IAMT) for treatment of acute ischemic (non-bleeding) stroke (AIS).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:

• Age 18 and \< 80

• Clinical evidence of acute ischemic (non-bleeding) stroke (AIS) with NIH Stroke Scale of 6 or higher

• Non-contrast Computed tomography (CT) Head with ASPECT (Alberta Stroke Program Early CT) score 6

• Symptom onset began \< 16 hours from initiation of intra-arterial mechanical thrombectomy (IAMT) procedure

• CT Angiogram (CTA) evidence of anterior circulation MCA (Middle Cerebral Artery) M1 segment occlusion.

• CT Perfusion (CTP) evidence of core infarct volume of \< 70ml and a ratio of ischemic tissue to initial core infarct volume of 1.8 or greater, and an absolute volume of penumbra of 15ml or greater

• Patient or patient's representative provides consent

• Pre-stroke modified Rankin Scale (mRS) of \< =2

• General endotracheal anesthesia (GETA) is planned to be used, as standard care, for IAMT

• Treatment with iNO requires mechanical ventilation. Because IAMT can be performed using conscious sedation and not GETA, only those patients for which the procedure is planned with GETA will be included. The decision for the type of anesthetic depends on the severity of stroke, region of brain affected by the stroke, and the ability for the patient to cooperate for the procedure.

Locations
United States
North Carolina
Atrium Health
RECRUITING
Charlotte
Carolinas Medical Center
RECRUITING
Charlotte
Contact Information
Primary
Anna M Helms, MSN, RN
anna.m.helms@advocatehealth.org
704-446-0473
Backup
Clara Schommer, CCRP
clara.schommer@advocatehealth.org
704-355-9434
Time Frame
Start Date: 2025-11-11
Estimated Completion Date: 2028-12
Participants
Target number of participants: 36
Treatments
Experimental: Dose 2 Group
Dose 2- Inhaled Nitrous Oxide (iNO) 40ppm.
Experimental: Dose 3 Group
Dose 3- Inhaled Nitrous Oxide (iNO) 50ppm.
Experimental: Dose 4 Group
Dose 4- Inhaled Nitrous Oxide (iNO) 60ppm.
Experimental: Dose 5 Group
Dose 5- Inhaled Nitrous Oxide (iNO) 70ppm.
Experimental: Dose 6 Group
Dose 6- Inhaled Nitrous Oxide (iNO) 80ppm.
Experimental: Dose 1 Group
Dose 1- Inhaled Nitrous Oxide (iNO) 20ppm.
Related Therapeutic Areas
Sponsors
Leads: Wake Forest University Health Sciences

This content was sourced from clinicaltrials.gov